Happy birthday Cristiane D Bergerot 🥰🥰🥰🥰🥰🥰🥰🥰🥰🥰🥰

🚨Deadline approaching! You still have time to submit your abstract for #ASCOQLTY25! We’re seeking innovative, data-driven work in 💡Cost, Value & Policy 🌍Access & Disparities 💙PallCare 🗣️Patient Experience ⚙️Quality & Safety 🌱Survivorship 📲Tech & Innovation 📅 Submit now!

Discusión de la última mesa, sobre cáncer de vejiga. ⁦Teresa Bonfill⁩ y Ricardo Fernández. ⁦Arancha Glez del Alba⁩ ⁦Mjose MendezVidal⁩ ⁦Bego PValderrama⁩

A GREAT START OF #EHA25 🩸 Lets Go to #MEDTRACK for Stats Follow MEDTRACK HERE👉 MEDTRACK ⚕️ my.medical.watch/oncoalert/hash… MEDTRACK brought to you by OncoAlert 🚨 & Medical.watch ⭐️GREAT ENGAGEMENT ON DAY ONE Metrics from June 11-12, 2025 EHA Contributors

🌟Adjuvant IO in RCC is here — but what really drives your choice? OncoAlert 🟠RFS, OS, QoL, or access? This poll nails the real-life decision-making dilemma. Sumanta K. Pal, MD, FASCO Petros Grivas Giuseppe Banna Ravindran Kanesvaran Laurence Albiges Neeraj Agarwal, MD, FASCO 👇 Cast your vote & share how you prioritize in

Impact of germline vs somatic BRCA mutation status on the efficacy of rucaparib vs physician’s choice in the TRITON3 study of patients with metastatic castration-resistant prostate cancer. (Poster in #ASCO25 ) meetings.asco.org/abstracts-pres… In the phase 3 TRITON3 study, rucaparib

Wonderful initiative! Kudos to Vedang Murthy exactly spirit of Advanced Prostate Cancer Consensus Conference to spread knowledge and initiate discussions. Recommendations have to be adapted to regional specifities. Hope to see many South Asians Advanced Prostate Cancer Consensus Conference in Lugano 30th April, registration anar rahimov.org

🌟🎓👏👏👏HUGE Congratulations, Toni Choueiri, MD, for your outstanding contribution to advancing knowledge and transforming the way we treat and understand genitourinary cancers. 🌟Your dedication, leadership, and vision continue to inspire a generation of oncologists around the

⚡️ Molecular subtyping of urothelial carcinoma using just 4 common IHC markers (GATA3, KRT5, KRT14, KRT20). - Cost-effective, clinically relevant - Luminal subtype linked to better OS - Valuable for early stratification in limited-resource settings journals.lww.com/appliedimmunoh…

We Are ALL OncoAlert 🚨 3⃣9⃣k of our Oncology Colleagues & Going STRONG ...and we are JUST Getting Started Entirely by Colleagues.....For Colleagues🌐 Our Gratitude for your support! Gil Morgan, MD #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD, PhD Emre Yekedüz

Excited to see our work published in Clinical Cancer Research ! Real-world pts w/ mHSPC #prostatecancer w/ HRRalt had worse survival than those w/ non-altered HRR 👉bit.ly/3TsOw9i👇 Grateful for terrific support from team Ryon Graf, PhD Umang Swami Neeraj Agarwal, MD, FASCO UroToday.com OncoAlert

🚨 Our new study alert! Elsevier What is the role of comorbidity burden in response to immunotherapy based combos in patients with metastatic renal cell carcinoma? 🎯Endpoints : Overall surival and time to treatment failure High comorbidity 🟰 Worse Outcomes ❓❗️No

Comorbidity Burden and Effectiveness of Immunotherapy in Metastatic Renal Cell Carcinoma clinical-genitourinary-cancer.com/article/S1558-… This study investigated the impact of pre-existing medical conditions (comorbidities) on outcomes for 304 patients with metastatic renal cell carcinoma (mRCC)

A warm invitation to MEDTALK at ESMO 2025, hosted by MEDSIR Register: buff.ly/uLHrrkY October 19th, 7:00 PM–8:30 PM in Berlin, Germany. Explore how theranostics is revolutionizing oncology by uniting diagnostic imaging and targeted therapy to offer new hope for

Association between serum 25-hydroxyvitamin D and #ProstateCancer in middle-aged and elderly Americans: a national population-based analysis of NHANES 2001–2018 bmccancer.biomedcentral.com/articles/10.11… A cross-sectional study utilizing data from the National Health and Nutrition Examination

The gut doesn’t stay in the gut!!! 🧠 T cells trained in the gut can storm the brain!!! nature OncoAlert rdcu.be/erGig

Out in NEJM!! 🚨 Breakthrough in HLRCC-associated RCC! A Phase 2 trial shows that 💉bevacizumab + erlotinib offers high efficacy in advanced papillary renal cell carcinoma: 🔬 HLRCC-associated pRCC: ✅ 72% response rate ⏱️ Median PFS: 21.1 mo 💀 Median OS: 44.6+ mo 🔬 Sporadic

Last chance to register FREE for #IUCS25 in Portsmouth or online! Join leading experts in urology cancer on Sept 4-5 for cutting-edge science & networking. Submit your abstract by June 30 for poster & mini-oral! 🔗 Register & submit: urologycancersummit.org #Urology OncoAlert

An excellent review on optimising treatment of stage 2 seminoma. Very well written highlighting the double edge sword - efficacy and toxicity. doi.org/10.1200/OP-25-… Toni Choueiri, MD UroToday.com Jonathan Rosenberg MD Bradley McGregor Karine Tawagi MD Rana McKay, MD, FASCO Matt Galsky Bhardwaj Lab